[ APPLICATION NOTE ] Analysis of Genotoxic Impurities of Imatinib Mesylate by LC-MS from Early Development to Routine Monitoring Margaret Maziarz and Mark Wrona Waters Corporation, Milford, MA, USA APPLICATION BENEFITS ■■ ■■ ■■ INTRODUCTION Sensitive and selective UPLC® method…
Klíčová slova
mpba, pnmp, genotoxic, imatinib, mesylate, impurities, xevo, acquity, micro, qda, monitoring, early, mrm, uplc, development